Santen Pharmaceutical Co (Santen Pharmaceutical Co) Change In Receivables : $67 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Change In Receivables?

Santen Pharmaceutical Co's change in receivables for the quarter that ended in Dec. 2023 was $58 Mil. It means Santen Pharmaceutical Co's Accounts Receivable declined by $58 Mil from Sep. 2023 to Dec. 2023 .

Santen Pharmaceutical Co's change in receivables for the fiscal year that ended in Mar. 2023 was $-48 Mil. It means Santen Pharmaceutical Co's Accounts Receivable increased by $48 Mil from Mar. 2022 to Mar. 2023 .

Santen Pharmaceutical Co's Accounts Receivable for the quarter that ended in Dec. 2023 was $590 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Santen Pharmaceutical Co's Days Sales Outstanding for the three months ended in Dec. 2023 was 100.62.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Santen Pharmaceutical Co's liquidation value for the three months ended in Dec. 2023 was $283 Mil.

Santen Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Santen Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Change In Receivables Chart

Santen Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Receivables

Get a 7-Day Free Trial

-56.71

-28.37

-69.13

-16.57

-48.20

Santen Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-57.10	-94.02	33.72	69.55	57.67

Santen Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $67 Mil.

Santen Pharmaceutical Co (OTCPK:SNPHY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Santen Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	589.902	/	534.978	*	91
=	100.62

2. In Ben Graham's calculation of liquidation value, Santen Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Santen Pharmaceutical Co's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	578.949	-	901.755	+	0.75 * 589.902	+	0.5 * 325.896
=	283

Santen Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SNPHF:USA 4536:Japan SZD:Germany

Address

Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552

Website

http://www.santen.co.jp

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020